Hutchison China MediTech Limited (HCM): Price and Financial Metrics
GET POWR RATINGS... FREE!
HCM POWR Grades
- Sentiment is the dimension where HCM ranks best; there it ranks ahead of 90.29% of US stocks.
- The strongest trend for HCM is in Value, which has been heading up over the past 31 weeks.
- HCM's current lowest rank is in the Quality metric (where it is better than 8.18% of US stocks).
HCM Stock Summary
- Of note is the ratio of HUTCHMED (China) Ltd's sales and general administrative expense to its total operating expenses; just 12.72% of US stocks have a lower such ratio.
- HCM's price/sales ratio is 18.64; that's higher than the P/S ratio of 89.1% of US stocks.
- With a year-over-year growth in debt of 393.03%, HUTCHMED (China) Ltd's debt growth rate surpasses 96.86% of about US stocks.
- Stocks that are quantitatively similar to HCM, based on their financial statements, market capitalization, and price volatility, are OCFT, TARO, AUMN, VNE, and NEON.
- Visit HCM's SEC page to see the company's official filings. To visit the company's web site, go to www.hutch-med.com.
HCM Stock Price Chart Interactive Chart >
HCM Price/Volume Stats
|Current price||$37.54||52-week high||$43.94|
|Prev. close||$38.41||52-week low||$23.67|
|Day high||$38.08||Avg. volume||306,195|
|50-day MA||$39.87||Dividend yield||N/A|
|200-day MA||$32.77||Market Cap||6.49B|
Hutchison China MediTech Limited (HCM) Company Bio
Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in China. The company was founded in 2000 and is based in Hong Kong, Hong Kong.
Most Popular Stories View All
HCM Latest News Stream
|Loading, please wait...|
HCM Latest Social Stream
View Full HCM Social Stream
Latest HCM News From Around the Web
Below are the latest news stories about HUTCHMED (China) Ltd that investors may wish to consider to help them evaluate HCM as an investment opportunity.
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma
HONG KONG and SHANGHAI, China and FLORHAM PARK, N,J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (“FL”), a subtype of non-Hodgkin’s lympho
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
— Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mutations or aberrations of EGFR and MET —HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:AZN) have initiated SANOVO, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase i
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3Kδ inhibitor HMPL-689), savolitinib (ORPATHYS® in China) and fruquintinib (ELUNATE® in China) will be presented at the upcoming 2021 European Society for Medical Oncology (“ESMO”) Virtual Congress taking place on September 16-21, 2021. AMDIZALISIB (also known
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 06, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Company’s ordinary shares, which trade on The Stock Exchange of Hong Kong Limited (“HKEX”), are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on September 6, 2021, according to announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange
HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 25, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer (“TNBC”) or advanced endometrial cancer (“EC”) in the U.S. The first patient was dosed on August 24, 2021. This trial is to explore the potential for the addition of a highly selective vascular endo
HCM Price Returns
Continue Researching HCMWant to see what other sources are saying about Hutchison China MediTech Ltd's financials and stock price? Try the links below:
Hutchison China MediTech Ltd (HCM) Stock Price | Nasdaq
Hutchison China MediTech Ltd (HCM) Stock Quote, History and News - Yahoo Finance
Hutchison China MediTech Ltd (HCM) Stock Price and Basic Information | MarketWatch